Search Results - bernard+moss

13 Results

Sort By:

WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene

Mutation in gene A34R can regulate the release of progeny virions from the surface of parental cells.

Published: 7/25/2024 | Inventor(s): Rafael Blasco, Bernard Moss

Keywords(s): A34, AC4XXX, AC5XXX, ACXXXX, AXXXXX, Cell, DDXXXX, DISSOCIATION, DXXXXX, GCXXXX, GLYCOPROTEIN, MEMBRANE, Progeny, REGULATED, research, RESEARCH MATERIAL, research reagent, RESEARCH TOOL, RM, RXXXXX, vaccinia, viral, virus, WIXXXX, XEXXXX, XKXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease

A Novel Virus-Based Expression System

The present invention is related to a recombinant viral vector for vaccines. Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response. The present novel virus-based expression vectors...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Bernard Moss

Keywords(s): Expression, Gene, GENES, High, LOW, Non-Replicating, System, TARGET, vaccinia, Vector, virus, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WNXXXX, XEXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics

Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines

The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of...

Published: 7/25/2024 | Inventor(s): Patricia Earl, Linda Wyatt, Bernard Moss

Keywords(s): ANKARA, Del, Expression, Fied, Foreign, GB1DXX, GB1XXX, GBXXXX, Gene, GENES, GXXXXX, INCREASE, Insertion, LIl, Modi, Modified, MVA, Patent Category - Biotechnology, PLASMID, SHUTTLE, SITE, STABILITY, vaccinia, Vector, virus

Category(s): Collaboration Sought > Licensing, Application > Therapeutics

Biological/Research Material for HIV Vaccine Research

Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines. Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Bernard Moss

Keywords(s): 239gagpol, ACXXXX, AXXXXX, DC5XXX, DCXXXX, DXXXXX, EXPRESSES, Gene, MVA/SIV239gagpol, MVNSIV239gagpoi, PJH4, recombinant, RESEARCH MATERIAL, SIV, SIV239gagpol, That, virus

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Biological/Research Material for H1N1 Influenza Virus Vaccine Research

Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice. The materials can be used for research purposes and in particular in the area of influenza virus...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Bernard Moss

Keywords(s): A/PR/8/34, Attenuated, AXXXXX, DCXXXX, DDXXXX, DXXXXX, EXPRESSES, H1N1, Ha, Haemagglutinin, INFLUENZA, MVA, Np, NUCLEOPROTEIN, RESEARCH MATERIAL, That, vaccinia, virus

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

Recombinant Vaccines Based on Poxvirus Vectors

The technology offered for licensing is foundational in the area of recombinant DNA vaccines. In the last several years, facilitated through a licensing program of the NIH, the technology has been broadly applied in the development and commercialization of several novel human and veterinary vaccines in the areas of infectious disease as well as cancer...

Published: 7/25/2024 | Inventor(s): Bernard Moss

Keywords(s): B, BBXXXX, BCXXXX, DC5BXX, DC5XXX, DCXXXX, Duke DNA Project, Hepatitis, INFLUENZA, POX VIRUS, rabies, recombinant, vaccines, vaccinia, virus, VLXXXX, VOXXXX, WNXXXX, XKXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Consumer Products, TherapeuticArea > Infectious Disease

HIV Monoclonal Antibodies

This technology describes several hybridomas that produce monoclonal antibodies (mAbs) useful in HIV research applications. The mAbs are specific for either gp41 or gp120. In particular, the hybridomas producing mAbs designated D19, D56, M12, T8 and T24 (all anti-gp120), and T32 and T33 (gp41 specific) were found to be of particular utility. Additional...

Published: 7/25/2024 | Inventor(s): Patricia Earl, Christopher Broder, Robert Doms, Bernard Moss

Keywords(s): 597-613, Anti-gp41, DDXXXX, DXXXXX, mabs, T32, T33, T40, VLXXXX, WIXXXX

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, TherapeuticArea > Infectious Disease

Monoclonal Antibodies Against Orthopoxviruses

Concerns that variola (smallpox) virus might be used as a biological weapon have led to the recommendation of widespread vaccination with vaccinia virus. While vaccination is generally safe and effective for prevention of smallpox, it is well documented that various adverse reactions in individuals have been caused by vaccination with existing licensed...

Published: 7/25/2024 | Inventor(s): Bernard Moss, Suzanne Emerson, Robert Purcell, Patricia Earl, Zhaochun Chen

Keywords(s): Against, antibodies, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, monoclonal, ORTHOPOXVIRUSES

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes

Since the onset of the AIDS epidemic more than two decades ago, enormous efforts have been directed to making a vaccine that will protect against human immunodeficiency virus-1 (HIV); an effective vaccine is thought to require the induction of cellular and humoral responses. Vaccine candidates have included a variety of HIV immunogens delivered as...

Published: 7/25/2024 | Inventor(s): Patricia Earl, Linda Wyatt, Bernard Moss

Keywords(s): Alteration, Alternation, BETWEEN, Clinical, CODON, Constructs, DC5AXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Enhanced, ESSENTIAL, Foreign, Gene, Genebetween, GENES, Hyper IgM syndrome, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Insertion, Inserts, Mechanism, MVA/HIV1, PLASMID, recombinant, Severe combined immunodeficiency, x-linked, SHUTTLE, STABILITY, TWO, Vaccine, vaccinia, virus, Wiskott Aldrich syndrome

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Vaccines

Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development

The current technology relates to the construction, characterization and immunogenicity of modified vaccinia Ankara (MVA) recombinant viruses. The MVA double recombinant viruses express modified/truncated HIV-1 Env and mutated HIV Gag Pol under the control of vaccinia virus early/late promoters. This technology describes the MVA double recombinant...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Bernard Moss

Keywords(s): 47 XYY syndrome, DC5AXX, DCXXXX, Double Y, DXXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

1 2